School of Nursing, Shandong Second Medical University, Weifang, Shandong, China.
Department of Pathology, Shandong Second Medical University, Weifang, Shandong, China.
Ann Med. 2024 Dec;56(1):2396568. doi: 10.1080/07853890.2024.2396568. Epub 2024 Sep 14.
The clinical efficacy of cancer treatment protocols remains unsatisfactory; however, the emergence of ferroptosis-driven therapy strategies has renewed hope for tumor treatment, owing to their remarkable tumor suppression effects. Biologically based small-molecule inducers are used in conventional method to induce ferroptosis. Nevertheless, some molecular drugs have limited solubility, poor ability to target cells, and fast metabolism, which hinder their ability to induce ferroptosis over a prolonged period. Fortunately, further investigations of ferroptosis and the development of nanotechnology have demonstrated that nanoparticles (NPs) are more efficient in inducing ferroptosis than drugs alone, which opens up new perspectives for cancer therapy.
In order to organize a profile of recent advance in NPs for inducing ferroptosis in cancer therapy, and NPs were comprehensively classified in a new light.Materials and methods: We comprehensively searched the databases such as PubMed and Embase. The time limit for searching was from the establishment of the database to 2023.11. All literatures were related to "ferroptosis", "nanoparticles", "nanodelivery systems", "tumors", "cancer".
We summarized and classified the available NPs from a new perspective. The NPs were classified into six categories based on their properties: (1) iron oxide NPs (2) iron - based conversion NPs (3) core-shell structure (4) organic framework (5) silica NPs (6) lipoprotein NPs. According to the therapeutic types of NPs, they can be divided into categories: (1) NPs induced ferroptosis-related immunotherapy (2) NPs loaded with drugs (3) targeted therapy of NPs (4) multidrug resistance therapy (5) gene therapy with NPs (6) energy conversion therapy.
The insights gained from this review can provide ideas for the development of original NPs and nanodelivery systems, pave the way for related nanomaterials application in clinical cancer therapy, and advance the application and development of nanotechnology in the medical field.
癌症治疗方案的临床疗效仍不尽如人意;然而,铁死亡驱动的治疗策略的出现为肿瘤治疗带来了新的希望,因为它们具有显著的肿瘤抑制作用。在传统方法中,使用基于生物学的小分子诱导剂来诱导铁死亡。然而,一些分子药物的溶解度有限,靶向细胞的能力差,代谢速度快,这阻碍了它们在较长时间内诱导铁死亡的能力。幸运的是,对铁死亡的进一步研究和纳米技术的发展表明,纳米颗粒(NPs)在诱导铁死亡方面比单独使用药物更有效,这为癌症治疗开辟了新的视角。
为了全面了解 NPs 诱导铁死亡在癌症治疗中的最新进展,并从全新的角度对 NPs 进行全面分类。
我们全面检索了 PubMed 和 Embase 等数据库。搜索时间从数据库建立到 2023.11。所有文献均与“铁死亡”、“纳米颗粒”、“纳米递药系统”、“肿瘤”、“癌症”有关。
我们从全新的角度总结和分类了现有的 NPs。根据 NPs 的性质,将其分为六类:(1)氧化铁 NPs;(2)铁基转换 NPs;(3)核壳结构;(4)有机骨架;(5)二氧化硅 NPs;(6)脂蛋白 NPs。根据 NPs 的治疗类型,可分为以下几类:(1)NPs 诱导铁死亡相关免疫治疗;(2)NPs 载药;(3)NPs 靶向治疗;(4)多药耐药治疗;(5)NPs 基因治疗;(6)能量转换治疗。
本综述获得的见解可为原创 NPs 和纳米递药系统的开发提供思路,为相关纳米材料在临床癌症治疗中的应用铺平道路,并推进纳米技术在医学领域的应用和发展。